Cargando…

Theranostics in nuclear medicine practice

The importance of personalized medicine has been growing, mainly due to a more urgent need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Yordanova, Anna, Eppard, Elisabeth, Kürpig, Stefan, Bundschuh, Ralph A, Schönberger, Stefan, Gonzalez-Carmona, Maria, Feldmann, Georg, Ahmadzadehfar, Hojjat, Essler, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633297/
https://www.ncbi.nlm.nih.gov/pubmed/29042793
http://dx.doi.org/10.2147/OTT.S140671
_version_ 1783269865612640256
author Yordanova, Anna
Eppard, Elisabeth
Kürpig, Stefan
Bundschuh, Ralph A
Schönberger, Stefan
Gonzalez-Carmona, Maria
Feldmann, Georg
Ahmadzadehfar, Hojjat
Essler, Markus
author_facet Yordanova, Anna
Eppard, Elisabeth
Kürpig, Stefan
Bundschuh, Ralph A
Schönberger, Stefan
Gonzalez-Carmona, Maria
Feldmann, Georg
Ahmadzadehfar, Hojjat
Essler, Markus
author_sort Yordanova, Anna
collection PubMed
description The importance of personalized medicine has been growing, mainly due to a more urgent need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of potential targets can help predict if a patient will benefit from a particular treatment. Thanks to the quick development of radiopharmaceuticals and diagnostic techniques, the use of theranostic agents has been continually increasing. In this article, important milestones of nuclear therapies and diagnostics in the context of theranostics are highlighted. It begins with a well-known radioiodine therapy in patients with thyroid cancer and then progresses through various approaches for the treatment of advanced cancer with targeted therapies. The aim of this review was to provide a summary of background knowledge and current applications, and to identify the advantages of targeted therapies and imaging in nuclear medicine practices.
format Online
Article
Text
id pubmed-5633297
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56332972017-10-17 Theranostics in nuclear medicine practice Yordanova, Anna Eppard, Elisabeth Kürpig, Stefan Bundschuh, Ralph A Schönberger, Stefan Gonzalez-Carmona, Maria Feldmann, Georg Ahmadzadehfar, Hojjat Essler, Markus Onco Targets Ther Review The importance of personalized medicine has been growing, mainly due to a more urgent need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of potential targets can help predict if a patient will benefit from a particular treatment. Thanks to the quick development of radiopharmaceuticals and diagnostic techniques, the use of theranostic agents has been continually increasing. In this article, important milestones of nuclear therapies and diagnostics in the context of theranostics are highlighted. It begins with a well-known radioiodine therapy in patients with thyroid cancer and then progresses through various approaches for the treatment of advanced cancer with targeted therapies. The aim of this review was to provide a summary of background knowledge and current applications, and to identify the advantages of targeted therapies and imaging in nuclear medicine practices. Dove Medical Press 2017-10-03 /pmc/articles/PMC5633297/ /pubmed/29042793 http://dx.doi.org/10.2147/OTT.S140671 Text en © 2017 Yordanova et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Yordanova, Anna
Eppard, Elisabeth
Kürpig, Stefan
Bundschuh, Ralph A
Schönberger, Stefan
Gonzalez-Carmona, Maria
Feldmann, Georg
Ahmadzadehfar, Hojjat
Essler, Markus
Theranostics in nuclear medicine practice
title Theranostics in nuclear medicine practice
title_full Theranostics in nuclear medicine practice
title_fullStr Theranostics in nuclear medicine practice
title_full_unstemmed Theranostics in nuclear medicine practice
title_short Theranostics in nuclear medicine practice
title_sort theranostics in nuclear medicine practice
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633297/
https://www.ncbi.nlm.nih.gov/pubmed/29042793
http://dx.doi.org/10.2147/OTT.S140671
work_keys_str_mv AT yordanovaanna theranosticsinnuclearmedicinepractice
AT eppardelisabeth theranosticsinnuclearmedicinepractice
AT kurpigstefan theranosticsinnuclearmedicinepractice
AT bundschuhralpha theranosticsinnuclearmedicinepractice
AT schonbergerstefan theranosticsinnuclearmedicinepractice
AT gonzalezcarmonamaria theranosticsinnuclearmedicinepractice
AT feldmanngeorg theranosticsinnuclearmedicinepractice
AT ahmadzadehfarhojjat theranosticsinnuclearmedicinepractice
AT esslermarkus theranosticsinnuclearmedicinepractice